61828 Federal Register / Vol. 70, No. 206 / Wednesday, October 26, 2005 / Notices 

Dated: October 17, 2005. 

Robert E. Polson, 

Office of the Secretary, Paperwork Reduction 

Act Reports Clearance Officer. 

[FR Doc. 05–21356 Filed 10–25–05; 8:45 am] 

BILLING CODE 4168–17–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel; Meeting 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel: Enhancing Utilization 

of Childhood Immunization Client 

Recall Practices by Private Providers, 

RFA; IP 05–088; Improving Vaccination 

Coverage in the Greater than 65 Years of 

Age Population, RFA IP 05–091; 

Influenza Vaccination of Children and 

Accompanying Adults: Mass 

Vaccination versus Vaccination in 

Routine Care, RFA IP 05–094; 

Effectiveness of a Hospital Based 

Program for Vaccination of Birth 

Mothers and Household Contacts with 

Inactivated Influenza Vaccine, RFA; IP 

05–095; and Developing Methods and 

Strategies to Increase Use of 

Immunization Registries by Private 

Providers, RFA IP 05–096. 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting: 

Name: Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Enhancing 

Utilization of Childhood Immunization 

Client Recall Practices by Private 

Providers, RFA IP 05–088; Improving 

Vaccination Coverage in the Greater 

than 65 Years of Age Population, RFA 

IP 05–091; Influenza Vaccination of 

Children and Accompanying Adults: 

Mass Vaccination versus Vaccination in 

Routine Care, RFA IP 05–094; 

Effectiveness of a Hospital Based 

Program for Vaccination of Birth 

Mothers and Household Contacts with 

Inactivated Influenza Vaccine, RFA IP 

05–095; and Developing Methods and 

Strategies to Increase Use of 

Immunization Registries by Private 

Providers, RFA IP 05–096. 

Times and Dates: 8 a.m.–5 p.m., 

November 21, 2005 (Closed). 

Place: Renaissance Hotel, 1 Hartsfield 

Center Parkway, Atlanta, GA 30354, 

Telephone 404.209.9999. 

Status: The meeting will be closed to 

the public in accordance with 

provisions set forth in section 552b(c) 

(4) and (6), Title 5 U.S.C., and the 

Determination of the Director, 

Management Analysis and Services 

Office, CDC, pursuant to Public Law 92–

463. 

Matters to be Discussed: The meeting 

will include the review, discussion, and 

evaluation of applications received in 

response to Enhancing Utilization of 

Childhood Immunization Client Recall 

Practices by Private Providers, RFA IP 

05–088; Improving Vaccination 

Coverage in the Greater than 65 Years of 

Age Population, RFA IP 05–091; 

Influenza Vaccination of Children and 

Accompanying Adults: Mass 

Vaccination versus Vaccination in 

Routine Care, RFA IP 05–094; 

Effectiveness of a Hospital Based 

Program for Vaccination of Birth 

Mothers and Household Contacts with 

Inactivated Influenza Vaccine, RFA IP 

05–095; and Developing Methods and 

Strategies to Increase Use of 

Immunization Registries by Private 

Providers, RFA IP 05–096. 

FOR FURTHER INFORMATION CONTACT: 

Horace M. Stiles, PHD MPH DDS, 

Scientific Review Administrator, 

National Institute for Occupational 

Safety and Health, CDC, 1600 Clifton 

Road, NE., MS E–74, Atlanta, GA 30333, 

Telephone 404–498–2584. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: October 19, 2005. 

Alvin Hall, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 05–21341 Filed 10–25–05; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Vaccines and Related Biological 

Products Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). At least one portion of the 

meeting will be closed to the public. 

Name of Committee: Vaccines and 

Related Biological Products Advisory 

Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on November 16, 2005, from 8:30 

a.m. to 5:15 p.m. and on November 17, 

2005, from 8:30 a.m. to 5:30 p.m. 

Location: Holiday Inn Select, 8120 

Wisconsin Ave., Bethesda, MD. 

Contact Person: Christine Walsh or 

Denise Royster, Center for Biologics 

Evaluation and Research (HFM–71), 

Food and Drug Administration, 1401 

Rockville Pike, Rockville, MD 20852, 

301–827–0314, or FDA Advisory 

Committee Information Line, 1–800–

741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512391. Please call the Information 

Line for up-to-date information on this 

meeting. 

Agenda: On November 16, 2005, the 

committee will hear presentations and 

discuss the use of Madin-Darby Canine 

Kidney Cells for manufacture of 

Inactivated Influenza Vaccines. On 

November 17, 2005, the committee will 

discuss developing new Pneumococcal 

Vaccines for U.S. licensure for adults. 

Procedure: On November 16, 2005, 

from 8:30 a.m. to 5:15 p.m. and on 

November 17, 2005, from 10 a.m. to 5:30 

p.m., the meeting is open to the public. 

Interested persons may present data, 

information, or views, orally or in 

writing, on issues pending before the 

committee. Written submissions may be 

made to the contact person by 

November 9, 2005. Oral presentations 

from the public will be scheduled on 

November 16, 2005, between 

approximately 1:45 p.m. and 2:15 p.m. 

and on November 17, 2005, between 

approximately 1 p.m. and 1:30 p.m. 

Time allotted for each presentation may 

be limited. Those desiring to make 

formal oral presentations should notify 

the contact person before November 9, 

2005, and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation. 

Closed Committee Deliberations: On 

November 17, 2005, from 8:30 a.m. to 

9:55 a.m., the meeting will be closed to 

permit discussion and review of trade 

secret and/or confidential information 

(5 U.S.C. 552b(c)(4)). 

Persons attending FDA’s advisory 

committee meetings are advised that the